Carol Karp
General Counsel at PROTHENA CORPORATION PLC
Net worth: - $ as of 2024-04-29
Carol Karp active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PROTHENA CORPORATION PLC | General Counsel | 2016-12-14 | - |
| Rochester Christian University | Director/Board Member | - | - |
Career history of Carol Karp
Former positions of Carol Karp
| Companies | Position | Start | End |
|---|---|---|---|
| ESPERION THERAPEUTICS, INC. | Compliance Officer | 2012-12-31 | 2013-12-31 |
| General Counsel | 2012-12-31 | 2013-12-31 | |
| Janssen Alzheimer Immunotherapy | General Counsel | 2009-12-31 | 2012-12-31 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | General Counsel | - | 2011-05-01 |
| VIVUS, INC. | Corporate Officer/Principal | - | - |
| Powderject Technologies BV | Chief Tech/Sci/R&D Officer | - | - |
Training of Carol Karp
| Rochester Christian University | Undergraduate Degree |
| New York University | Undergraduate Degree |
Statistics
International
| United States | 7 |
| Netherlands | 2 |
| Ireland | 2 |
Operational
| General Counsel | 4 |
| Undergraduate Degree | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ESPERION THERAPEUTICS, INC. | Health Technology |
| PROTHENA CORPORATION PLC | Health Technology |
| Private companies | 4 |
|---|---|
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
| Powderject Technologies BV | |
| Janssen Alzheimer Immunotherapy |
- Stock Market
- Insiders
- Carol Karp
- Experience